|
Hearken to this text  |
Microbot Medical not too long ago accomplished the primary process in a scientific trial utilizing its surgical robotic system. Investigators within the firm’s pivotal human scientific trial accomplished the process at Brigham and Ladies’s Hospital (BWH) in Boston.
Liberty is a single-use endovascular system. No devoted infrastructure is required to make use of the system. This will decrease limitations to acquiring and utilizing the system, making the expertise obtainable to extra healthcare suppliers, claimed Microbot Medical. The corporate claims on its web site that lower than 1% of endovascular procedures are carried out robotically.
Surgeon’s used the Braintree, Massachusetts-based firm’s Liberty endovascular robotic surgical system. Dr. Dmitry Rabkin, the trial’s lead investigator, carried out the primary human case at BWH. The trial is a part of the corporate’s FDA investigational system exemption for Liberty, which it introduced final month. Microbot Medical expects to make use of the outcomes to help future FDA submissions and subsequent commercialization.
The corporate designed its Liberty surgical robotic for potential use in neurovascular, cardiovascular and peripheral vascular procedures. The system features a compact design and distant working capabilities to cut back radiation publicity and bodily pressure on physicians. Microbot believes Liberty’s distant operation might probably make it the primary system to democratize endovascular interventional procedures.
“Enrolling the primary affected person in our pivotal human scientific trial is a major milestone for the corporate, and an vital step on our journey to convey Liberty to U.S. physicians,” mentioned Dr. Juan Diaz-Cartelle, chief medical officer of Microbot Medical. “We’re very happy with the fast tempo of web site activation, and I’m wanting ahead to enrolling further sufferers within the close to future.”
Associated: 2024 surgical robotics outlook
Latest highlights for the corporate embody expanded U.S. operations forward of the IDE submission to organize for the subsequent steps. Microbot already had momentum after constructive outcomes from its good laboratory practices (GLP) pre-clinical research. The corporate additionally secured a $2.154 million settlement of a lawsuit involving a securities buy settlement in January.
Microbot Medical’s LIBERTY system is a single-use endovascular robotic surgical system. | Supply: Microbot Medical